StockNoteStockNote
CPC1 Hanoi Pharmaceutical Joint Stock Company (DTP) was established in 2009. The company operates mainly in the field of manufacturing drugs, pharmaceutical chemicals and medicinal materials. The company currently manufactures and sells more than 300 medicinal products and functional foods. DTP manages and operates the GMP - who pharmaceutical factory with an area of 3,360 m2. DTP is traded on UPCOM market from June 2020.
DTP currently has a market capitalization of roughly VND 2.353 billion, placing it in the mid-cap group on the Vietnamese stock market. Its current P/E of 8,6x is 16% below its own 7-year average (10,2x), suggesting the stock is trading cheaper than its historical norm. P/B stands at 1,8x, 25% below its multi-year average of 2,5x. Return on equity (ROE) is at 23,1%, down from 26,4% the year before. Its debt-to-equity ratio of 0,1x is low, reflecting a conservative capital structure. In 2025, revenue grew 31% year-on-year while after-tax profit grew 19%.
This note is generated automatically from the stock's real financial data, for reference only — not investment advice.
Unit: VND billion. Growth (%) vs. previous period.
Unit: VND billion. Year-end values; current year uses latest session.
Unit: x. Financial debt over shareholders' equity.
Data aggregated from cafef.vn and VNDirect, for reference only, not investment advice.